{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-064469","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.971174+00:00","generated_at":"2026-05-18T06:17:08.006497+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Onconetix agrees to reverse merger with Ocuvex; Ocuvex holders to own 90% of combined company","bullets":["Onconetix acquires Ocuvex; Ocuvex holders get 90% of combined co, Onconetix holders 10%.","Post-close board: 7 directors (5 Ocuvex, 2 Onconetix); closing targeted Q4 2025.","Series C Preferred conversion price reduced to $3.50 effective through July 31, 2025.","Andrew Oakley elected Lead Independent Director, to receive $36,000/month.","Nasdaq compliance regained; subject to Mandatory Panel Monitor through July 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-064469","json":"https://secwatch.observer/filing/0001213900-25-064469.json","markdown":"https://secwatch.observer/filing/0001213900-25-064469.md","text":"https://secwatch.observer/filing/0001213900-25-064469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025064469/0001213900-25-064469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025064469/ea0248815-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:17:08.006497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}